Transition from identity to bioactivity-guided proteomics for biomarker discovery with focus on the PF2D platform

Proteomics - Clinical Applications

Volumn 10, Issue 1, 2016, Pages 8-24

  Ménoret, Antoine ^a   Crocker, Stephen J ^a   Rodriguez, Annabelle ^a   Rathinam, Vijay A ^a   Clark, Robert B ^a   Vella, Anthony T ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Acute respiratory distress syndrome; Asthma; Atherosclerosis; Bioassay; Inflammation; Multiple sclerosis; Proteoform; PTMs; Validation assay

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN B; CYTOCHROME B5; CYTOKERATIN 17; HEAT SHOCK PROTEIN 27; INTERLEUKIN 6; INTERLEUKIN 8;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ASTHMA; ATHEROSCLEROSIS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FRACTIONATION; HUMAN; ISOELECTRIC FOCUSING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEOMICS; REVERSED PHASE LIQUID CHROMATOGRAPHY; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ANIMAL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; LUNG DISEASE; METABOLISM; PROCEDURES;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; LUNG DISEASES; PROTEOMICS;

EID: 84953360363     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201500029     Document Type: Review

References (223)

1. Altelaar, A. F., Munoz, J., Heck, A. J., Next-generation proteomics: towards an integrative view of proteome dynamics. Nat. Rev. Genet. 2013, 14, 35-48.
2. Smith, L. M., Kelleher, N. L., Proteoform: a single term describing protein complexity. Nat. Methods 2013, 10, 186-187.
3. Jensen, O. N., Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. Curr. Opin. Chem. Biol. 2004, 8, 33-41.
4. Okamoto, T., Miyazaki, Y., Shirahama, R., Tamaoka, M., Inase, N., Proteome analysis of bronchoalveolar lavage fluid in chronic hypersensitivity pneumonitis. Allergol. Int. 2011, 61, 83-92.
5. Okano, T., Kondo, T., Kakisaka, T., Fujii, K. et al., Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006, 6, 3938-3948.
6. Lilja-Maula, L. I., Palviainen, M. J., Heikkila, H. P., Raekallio, M. R., Rajamaki, M. M., Proteomic analysis of bronchoalveolar lavage fluid samples obtained from West Highland White Terriers with idiopathic pulmonary fibrosis, dogs with chronic bronchitis, and healthy dogs. Am. J. Vet. Res. 2012, 74, 148-154.
7. Farias, A. S., Martins-de-Souza, D., Guimaraes, L., Pradella, F. et al., Proteome analysis of spinal cord during the clinical course of monophasic experimental autoimmune encephalomyelitis. Proteomics 2012, 12, 2656-2662.
8. Dumont, D., Noben, J. P., Raus, J., Stinissen, P., Robben, J., Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 2004, 4, 2117-2124.
9. Liu, S., Bai, S., Qin, Z., Yang, Y. et al., Quantitative proteomic analysis of the cerebrospinal fluid of patients with multiple sclerosis. J. Cell Mol. Med. 2009, 13, 1586-1603.
10. Kaga, E., Karademir, B., Baykal, A. T., Ozer, N. K., Identification of differentially expressed proteins in atherosclerotic aorta and effect of vitamin E. J. Proteomics 2013, 92, 260-273.
11. Ando, T., Nagai, K., Chikada, M., Okamoto, K. et al., Proteomic analyses of aortic wall in patients with abdominal aortic aneurysm. J. Cardiovasc. Surg. 2011, 52, 545-555.
12. Yu, C. J., Wang, C. L., Wang, C. I., Chen, C. D. et al., Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology. J. Proteome Res. 2011, 10, 4671-4682.
13. Gao, W. M., Chadha, M. S., Berger, R. P., Omenn, G. S. et al., A gel-based proteomic comparison of human cerebrospinal fluid between inflicted and non-inflicted pediatric traumatic brain injury. J. Neurotrauma. 2007, 24, 43-53.
14. Xie, L., Terrand, J., Xu, B., Tsaprailis, G. et al., Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc. Res. 2010, 87, 628-635.
15. Rithidech, K. N., Honikel, L., Milazzo, M., Madigan, D. et al., Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Mult. Scler. 2009, 15, 455-464.
16. Stoop, M. P., Dekker, L. J., Titulaer, M. K., Burgers, P. C. et al., Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008, 8, 1576-1585.
17. Yu, H. R., Kuo, H. C., Sheen, J. M., Wang, L. et al., A unique plasma proteomic profiling with imbalanced fibrinogen cascade in patients with Kawasaki disease. Pediatr. Allergy Immunol. 2009, 20, 699-707.
18. Kap-Soon, N., Do-Youn, L., Hak, C. J., Joo, W. A. et al., Protein biomarkers in the plasma of workers occupationally exposed to polycyclic aromatic hydrocarbons. Proteomics 2004, 4, 3505-3513.
19. Hammack, B. N., Fung, K. Y., Hunsucker, S. W., Duncan, M. W. et al., Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult. Scler. 2004, 10, 245-260.
20. Liu, T., Donahue, K. C., Hu, J., Kurnellas, M. P. et al., Identification of differentially expressed proteins in experimental autoimmune encephalomyelitis (EAE) by proteomic analysis of the spinal cord. J. Proteome Res. 2007, 6, 2565-2575.
21. Lull, M. E., Carkaci-Salli, N., Freeman, W. M., Myers, J. L. et al., Plasma biomarkers in pediatric patients undergoing cardiopulmonary bypass. Pediatr. Res. 2008, 63, 638-644.
22. Iwanowski, P., Losy, J., Immunological differences between classical phenothypes of multiple sclerosis. J. Neurol. Sci. 2015, 349, 10-14.
23. De Masi, R., Vergara, D., Pasca, S., Acierno, R. et al., PBMCs protein expression profile in relapsing IFN-treated multiple sclerosis: a pilot study on relation to clinical findings and brain atrophy. J. Neuroimmunol. 2009, 210, 80-86.
24. Almeras, L., Lefranc, D., Drobecq, H., de Seze, J. et al., New antigenic candidates in multiple sclerosis: identification by serological proteome analysis. Proteomics 2004, 4, 2184-2194.
25. Wilson, M. E., Boumaza, I., Lacomis, D., Bowser, R., Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS One 2010, 5, e15133.
26. Rosenling, T., Attali, A., Luider, T. M., Bischoff, R., The experimental autoimmune encephalomyelitis model for proteomic biomarker studies: from rat to human. Clin. Chim. Acta 2011, 412, 812-822.
27. Uzun, L., Armutcu, C., Bicen, O., Ersoz, A. et al., Simultaneous depletion of immunoglobulin G and albumin from human plasma using novel monolithic cryogel columns. Colloids Surf. B Biointerfaces 2013, 112, 1-8.
28. Haudenschild, D. R., Eldridge, A., Lein, P. J., Chromy, B. A., High abundant protein removal from rodent blood for biomarker discovery. Biochem. Biophys. Res. Commun. 2014, 455, 84-89.
29. Henning, A. K., Albrecht, D., Riedel, K., Mettenleiter, T. C., Karger, A., An alternative method for serum protein depletion/enrichment by precipitation at mildly acidic pH values and low ionic strength. Proteomics 2015, 11, 1935-1940.
30. Steinman, L., Zamvil, S. S., How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 2006, 60, 12-21.
31. Dagley, L. F., Emili, A., Purcell, A. W., Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis. Proteomics Clin. Appl. 2012, 7, 91-108.
32. Farias, A. S., Pradella, F., Schmitt, A., Santos, L. M., Martins-de-Souza, D., Ten years of proteomics in multiple sclerosis. Proteomics 2013, 14, 467-480.
33. Han, M. H., Hwang, S. I., Roy, D. B., Lundgren, D. H. et al., Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 2008, 451, 1076-1081.
34. Grant, J. E., Hu, J., Liu, T., Jain, M. R. et al., Post-translational modifications in the rat lumbar spinal cord in experimental autoimmune encephalomyelitis. J. Proteome Res. 2007, 6, 2786-2791.
35. Morgan, L., Shah, B., Rivers, L. E., Barden, L. et al., Inflammation and dephosphorylation of the tight junction protein occludin in an experimental model of multiple sclerosis. Neuroscience 2007, 147, 664-673.
36. Gresle, M. M., Shaw, G., Jarrott, B., Alexandrou, E. N. et al., Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2008, 86, 3548-3555.
37. Norgren, N., Sundstrom, P., Svenningsson, A., Rosengren, L. et al., Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004, 63, 1586-1590.
38. Petzold, A., Gveric, D., Groves, M., Schmierer, K. et al., Phosphorylation and compactness of neurofilaments in multiple sclerosis: indicators of axonal pathology. Exp. Neurol. 2008, 213, 326-335.
39. Proia, P., Schiera, G., Salemi, G., Ragonese, P. et al., Neuronal and BBB damage induced by sera from patients with secondary progressive multiple sclerosis. Int. J. Mol. Med. 2009, 24, 743-747.
40. Blecharz, K. G., Haghikia, A., Stasiolek, M., Kruse, N. et al., Glucocorticoid effects on endothelial barrier function in the murine brain endothelial cell line cEND incubated with sera from patients with multiple sclerosis. Mult. Scler. 2010, 16, 293-302.
41. Kidd, B. A., Ho, P. P., Sharpe, O., Zhao, X. et al., Epitope spreading to citrullinated antigens in mouse models of autoimmune arthritis and demyelination. Arthritis Res. Ther. 2008, 10, R119.
42. Kim, J. K., Mastronardi, F. G., Wood, D. D., Lubman, D. M. et al., Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis. Mol. Cell Proteomics 2003, 2, 453-462.
43. Moscarello, M. A., Mastronardi, F. G., Wood, D. D., The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem. Res. 2007, 32, 251-256.
44. Qi, X., Lewin, A. S., Sun, L., Hauswirth, W. W., Guy, J., Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J. Biol. Chem. 2006, 281, 31950-31962.
45. Kolln, J., Ren, H. M., Da, R. R., Zhang, Y. et al., Triosephosphate isomerase- and glyceraldehyde-3-phosphate dehydrogenase-reactive autoantibodies in the cerebrospinal fluid of patients with multiple sclerosis. J. Immunol. 2006, 177, 5652-5658.
46. Witte, M. E., Bo, L., Rodenburg, R. J., Belien, J. A. et al., Enhanced number and activity of mitochondria in multiple sclerosis lesions. J. Pathol. 2009, 219, 193-204.
47. LeBeau, A. M., Sevillano, N., Markham, K., Winter, M. B. et al., Imaging active urokinase plasminogen activator in prostate cancer. Cancer Res. 2015, 75, 1225-1235.
48. Viola, K. L., Sbarboro, J., Sureka, R., De, M. et al., Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. Nat. Nanotechnol. 2015, 10, 91-98.
49. Braunwald, E., Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N. Engl. J. Med. 1997, 337, 1360-1369.
50. Zimmer, S., Grebe, A., Latz, E., Danger signaling in atherosclerosis. Circ. Res. 2015, 116, 323-340.
51. Narula, J., Strauss, H. W., The popcorn plaques. Nat. Med. 2007, 13, 532-534.
52. Fernandez-Friera, L., Ibanez, B., Fuster, V., Imaging subclinical atherosclerosis: is it ready for prime time? A review. J. Cardiovasc. Transl. Res. 2014, 7, 623-634.
53. Wang, T. J., Gona, P., Larson, M. G., Tofler, G. H. et al., Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 2006, 355, 2631-2639.
54. Musunuru, K., Blumenthal, R. S., Biomarkers for prediction of cardiovascular events. N. Engl. J. Med. 2007, 356, 1472; author reply 1474-1475.
55. Napoli, C., Zullo, A., Picascia, A., Infante, T., Mancini, F. P., Recent advances in proteomic technologies applied to cardiovascular disease. J. Cell Biochem. 2012, 114, 7-20.
56. Shalhoub, J., Sikkel, M. B., Davies, K. J., Vorkas, P. A. et al., Systems biology of human atherosclerosis. Vasc. Endovasc. Surg. 2014, 48, 5-17.
57. Eberini, I., Wait, R., Calabresi, L., Sensi, C. et al., A proteomic portrait of atherosclerosis. J. Proteomics 2013, 82, 92-112.
58. Gordon, S. M., Deng, J., Lu, L. J., Davidson, W. S., Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J. Proteome Res. 2010, 9, 5239-5249.
59. Vaisar, T., Mayer, P., Nilsson, E., Zhao, X. Q. et al., HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin. Chim. Acta 2010, 411, 972-979.
60. Lepedda, A. J., Cigliano, A., Cherchi, G. M., Spirito, R. et al., A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis 2009, 203, 112-118.
61. de la Cuesta, F., Barderas, M. G., Calvo, E., Zubiri, I. et al., Secretome analysis of atherosclerotic and non-atherosclerotic arteries reveals dynamic extracellular remodeling during pathogenesis. J. Proteomics 2011, 75, 2960-2971.
62. Malaud, E., Piquer, D., Merle, D., Molina, L. et al., Carotid atherosclerotic plaques: proteomics study after a low-abundance protein enrichment step. Electrophoresis 2012, 33, 470-482.
63. de la Cuesta, F., Alvarez-Llamas, G., Maroto, A. S., Donado, A. et al., A proteomic focus on the alterations occurring at the human atherosclerotic coronary intima. Mol. Cell Proteomics 2011, 10, M110 003517.
64. Seibert, T. A., Hibbert, B., Chen, Y. X., Rayner, K. et al., Serum heat shock protein 27 levels represent a potential therapeutic target for atherosclerosis: observations from a human cohort and treatment of female mice. J. Am. Coll. Cardiol. 2013, 62, 1446-1454.
65. Martin-Ventura, J. L., Duran, M. C., Blanco-Colio, L. M., Meilhac, O. et al., Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation 2004, 110, 2216-2219.
66. Jozefowicz-Okonkwo, G., Wierzbowska-Drabik, K., Kasielski, M., Trzos, E. et al., Is Hsp27 a marker of myocardial ischaemia? Kardiol. Pol. 2009, 67, 947-952.
67. Kardys, I., Rifai, N., Meilhac, O., Michel, J. B. et al., Plasma concentration of heat shock protein 27 and risk of cardiovascular disease: a prospective, nested case-control study. Clin. Chem. 2008, 54, 139-146.
68. Ghayour-Mobarhan, M., Saber, H., Ferns, G. A., The potential role of heat shock protein 27 in cardiovascular disease. Clin. Chim. Acta 2012, 413, 15-24.
69. Ghayour-Mobarhan, M., Sahebkar, A., Parizadeh, S. M., Moohebati, M. et al., Antibody titres to heat shock protein 27 are elevated in patients with acute coronary syndrome. Int. J. Exp. Pathol. 2008, 89, 209-215.
70. Azarpazhooh, M. R., Mobarra, N., Parizadeh, S. M., Tavallaie, S. et al., Serum high-sensitivity C-reactive protein and heat shock protein 27 antibody titers in patients with stroke and 6-month prognosis. Angiology 2010, 61, 607-612.
71. Blanco-Colio, L. M., Martin-Ventura, J. L., Carrero, J. J., Yilmaz, M. I. et al., Vascular proteomics and the discovery process of clinical biomarkers: the case of TWEAK. Proteomics Clin. Appl. 2011, 5, 281-288.
72. Blanco-Colio, L. M., Martin-Ventura, J. L., Munoz-Garcia, B., Orbe, J. et al., Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 916-922.
73. Sastre, C., Fernandez-Laso, V., Madrigal-Matute, J., Munoz-Garcia, B. et al., Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice. J. Cell Mol. Med. 2014, 18, 721-734.
74. Jelic-Ivanovic, Z., Bujisic, N., Spasic, S., Bogavac-Stanojevic, N. et al., Circulating sTWEAK improves the prediction of coronary artery disease. Clin. Biochem. 2009, 42, 1381-1386.
75. Chorianopoulos, E., Rosenberg, M., Zugck, C., Wolf, J. et al., Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur. J. Heart Fail 2009, 11, 1050-1056.
76. Martin-Ventura, J. L., Lindholt, J. S., Moreno, J. A., Vega de Ceniga, M. et al., Soluble TWEAK plasma levels predict expansion of human abdominal aortic aneurysms. Atherosclerosis 2010, 214, 486-489.
77. Turkmen, K., Tonbul, H. Z., Erdur, F. M., Toker, A. et al., Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol. 2013, 14, 144.
78. Sircar, G., Saha, B., Bhattacharya, S. G., Saha, S., Allergic asthma biomarkers using systems approaches. Front Genet 2014, 4, 308.
79. Lam, E., dos Santos, C. C., Advances in molecular acute lung injury/acute respiratory distress syndrome and ventilator-induced lung injury: the role of genomics, proteomics, bioinformatics and translational biology. Curr. Opin. Crit. Care 2008, 14, 3-10.
80. Barnett, N., Ware, L. B., Biomarkers in acute lung injury-marking forward progress. Crit. Care Clin. 2011, 27, 661-683.
81. Tunceroglu, H., Shah, A., Porhomayon, J., Nader, N. D., Biomarkers of lung injury in critical care medicine: past, present, and future. Immunol. Invest. 2013, 42, 247-261.
82. Terracciano, R., Pelaia, G., Preiano, M., Savino, R., Asthma and COPD proteomics: current approaches and future directions. Proteomics Clin. Appl. 2014, 9, 203-220.
83. Gharib, S. A., Nguyen, E. V., Lai, Y., Plampin, J. D. et al., Induced sputum proteome in healthy subjects and asthmatic patients. J. Allergy Clin. Immunol. 2011, 128, 1176-1184, e1176.
84. Bloemen, K., Van Den Heuvel, R., Govarts, E., Hooyberghs, J. et al., A new approach to study exhaled proteins as potential biomarkers for asthma. Clin. Exp. Allergy 2010, 41, 346-356.
85. Lee, T. H., Jang, A. S., Park, J. S., Kim, T. H. et al., Elevation of S100 calcium binding protein A9 in sputum of neutrophilic inflammation in severe uncontrolled asthma. Ann. Allergy Asthma Immunol. 2013, 111, 268-275, e261.
86. Roth, M. J., Parks, B. A., Ferguson, J. T., Boyne, M. T., 2nd, Kelleher, N. L., "Proteotyping": population proteomics of human leukocytes using top down mass spectrometry. Anal. Chem. 2008, 80, 2857-2866.
87. Markowitz, J., Carson, W. E., 3rd, Review of S100A9 biology and its role in cancer. Biochim. Biophys. Acta 2012, 1835, 100-109.
88. Halayko, A. J., Ghavami, S., S100A8/A9: a mediator of severe asthma pathogenesis and morbidity? Can. J. Physiol. Pharmacol. 2009, 87, 743-755.
89. Goyette, J., Geczy, C. L., Inflammation-associated S100 proteins: new mechanisms that regulate function. Amino Acids 2010, 41, 821-842.
90. Lim, S. Y., Raftery, M. J., Goyette, J., Geczy, C. L., S-glutathionylation regulates inflammatory activities of S100A9. J. Biol. Chem. 2010, 285, 14377-14388.
91. Schnapp, L. M., Donohoe, S., Chen, J., Sunde, D. A. et al., Mining the acute respiratory distress syndrome proteome: identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injury. Am. J. Pathol. 2006, 169, 86-95.
92. Ahasic, A. M., Zhai, R., Su, L., Zhao, Y. et al., IGF1 and IGFBP3 in acute respiratory distress syndrome. Eur. J. Endocrinol. 2011, 166, 121-129.
93. Lutmer, J., Watkins, D., Chen, C. L., Velten, M., Besner, G., Heparin-binding epidermal growth factor-like growth factor attenuates acute lung injury and multiorgan dysfunction after scald burn. J. Surg. Res. 2013, 185, 329-337.
94. Liu, D., Mao, P., Huang, Y., Liu, Y. et al., Proteomic analysis of lung tissue in a rat acute lung injury model: identification of PRDX1 as a promoter of inflammation. Mediators Inflamm. 2014, 2014, 469358.
95. Menoret, A., Kumar, S., Vella, A. T., Cytochrome b5 and cytokeratin 17 are biomarkers in bronchoalveolar fluid signifying onset of acute lung injury. PLoS One 2012, 7, e40184.
96. Chen, X., Shan, Q., Jiang, L., Zhu, B., Xi, X., Quantitative proteomic analysis by iTRAQ for identification of candidate biomarkers in plasma from acute respiratory distress syndrome patients. Biochem. Biophys. Res. Commun. 2013, 441, 1-6.
97. Chang, D. W., Hayashi, S., Gharib, S. A., Vaisar, T. et al., Proteomic and computational analysis of bronchoalveolar proteins during the course of the acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 2008, 178, 701-709.
98. Ware, L. B., Koyama, T., Zhao, Z., Janz, D. R. et al., Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit. Care 2013, 17, R253.
99. Agrawal, A., Zhuo, H., Brady, S., Levitt, J. et al., Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials. Am. J. Physiol. Lung Cell Mol. Physiol. 2012, 303, L634-L639.
100. Ware, L. B., Koyama, T., Billheimer, D. D., Wu, W. et al., Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010, 137, 288-296.
101. Liu, B., Yin, Q., Chen, Y. X., Zhao, Y. Z., Li, C. S., Role of Presepsin (sCD14-ST) and the CURB65 scoring system in predicting severity and outcome of community-acquired pneumonia in an emergency department. Respir. Med. 2014, 108, 1204-1213.
102. Aschner, Y., Zemans, R. L., Yamashita, C. M., Downey, G. P., Matrix metalloproteinases and protein tyrosine kinases: potential novel targets in acute lung injury and ARDS. Chest 2014, 146, 1081-1091.
103. Hemmer, B., Nessler, S., Zhou, D., Kieseier, B., Hartung, H. P., Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2006, 2, 201-211.
104. Trapp, B. D., Nave, K. A., Multiple sclerosis: an immune or neurodegenerative disorder? Annu. Rev. Neurosci. 2008, 31, 247-269.
105. Fakhoury, M., Role of immunity and inflammation in the pathophysiology of neurodegenerative diseases. Neurodegener. Dis. 2015, 15, 63-69.
106. Tsushima, K., King, L. S., Aggarwal, N. R., De Gorordo, A. et al., Acute lung injury review. Intern. Med. 2009, 48, 621-630.
107. Aggarwal, N. R., King, L. S., D'Alessio, F. R., Diverse macrophage populations mediate acute lung inflammation and resolution. Am. J. Physiol. Lung Cell Mol. Physiol. 2014, 306, L709-L725.
108. Han, S., Mallampalli, R. K., The acute respiratory distress syndrome: from mechanism to translation. J. Immunol. 2015, 194, 855-860.
109. Lambrecht, B. N., Hammad, H., The immunology of asthma. Nat. Immunol. 2014, 16, 45-56.
110. Shoenfeld, Y., Sherer, Y., Harats, D., Artherosclerosis as an infectious, inflammatory and autoimmune disease. Trends Immunol. 2001, 22, 293-295.
111. Hulsmans, M., Van Dooren, E., Holvoet, P., Mitochondrial reactive oxygen species and risk of atherosclerosis. Curr. Atheroscler. Rep. 2012, 14, 264-276.
112. Catherman, A. D., Skinner, O. S., Kelleher, N. L., Top down proteomics: facts and perspectives. Biochem. Biophys. Res. Commun. 2014, 445, 683-693.
113. Komatsu, S., Edman sequencing of proteins from 2D gels. Methods Mol. Biol. 2007, 355, 211-217.
114. Anderson, L., Six decades searching for meaning in the proteome. J. Proteomics 2014, 107, 24-30.
115. Vandermarliere, E., Mueller, M., Martens, L., Getting intimate with trypsin, the leading protease in proteomics. Mass Spectrom. Rev. 2013, 32, 453-465.
116. Hildonen, S., Halvorsen, T. G., Reubsaet, L., Why less is more when generating tryptic peptides in bottom-up proteomics. Proteomics 2014, 14, 2031-2041.
117. Soldi, M., Cuomo, A., Bonaldi, T., Improved bottom-up strategy to efficiently separate hypermodified histone peptides through ultra-HPLC separation on a bench top Orbitrap instrument. Proteomics 2014, 14, 2212-2225.
118. Stastna, M., Van Eyk, J. E., Post-translational modifications of lysine and evolving role in heart pathologies-recent developments. Proteomics 2014, 15, 1164-1180.
119. Burska, A. N., Hunt, L., Boissinot, M., Strollo, R. et al., Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators Inflamm. 2014, 2014, 492873.
120. Copeland, R. J., Han, G., Hart, G. W., O-GlcNAcomics-revealing roles of O-GlcNAcylation in disease mechanisms and development of potential diagnostics. Proteomics Clin. Appl. 2013, 7, 597-606.
121. Anbalagan, M., Huderson, B., Murphy, L., Rowan, B. G., Post-translational modifications of nuclear receptors and human disease. Nucl. Recept Signal. 2012, 10, e001.
122. Cargile, B. J., Bundy, J. L., Stephenson, J. L., Jr., Potential for false positive identifications from large databases through tandem mass spectrometry. J. Proteome Res. 2004, 3, 1082-1085.
123. Vuckovic, D., Dagley, L. F., Purcell, A. W., Emili, A., Membrane proteomics by high performance liquid chromatography-tandem mass spectrometry: analytical approaches and challenges. Proteomics 2012, 13, 404-423.
124. Chahrour, O., Cobice, D., Malone, J., Stable isotope labelling methods in mass spectrometry-based quantitative proteomics. J. Pharm. Biomed. Anal. 2015.
125. Calderon-Gonzalez, K. G., Valero Rustarazo, M. L., Labra-Barrios, M. L., Bazan-Mendez, C. I. et al., Determination of the protein expression profiles of breast cancer cell lines by quantitative proteomics using iTRAQ labelling and tandem mass spectrometry. J. Proteomics 2015, 124, 50-78.
126. Sajic, T., Liu, Y., Aebersold, R., Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications. Proteomics Clin. Appl. 2015, 9, 307-321.
127. Brun, V., Masselon, C., Garin, J., Dupuis, A., Isotope dilution strategies for absolute quantitative proteomics. J. Proteomics 2009, 72, 740-749.
128. Craft, G. E., Chen, A., Nairn, A. C., Recent advances in quantitative neuroproteomics. Methods 2013, 61, 186-218.
129. Lanucara, F., Eyers, C. E., Top-down mass spectrometry for the analysis of combinatorial post-translational modifications. Mass Spectrom. Rev. 2012, 32, 27-42.
130. Gregorich, Z. R., Ge, Y., Top-down proteomics in health and disease: challenges and opportunities. Proteomics 2014, 14, 1195-1210.
131. Fonslow, B. R., Yates, J. R., 3rd, Capillary electrophoresis applied to proteomic analysis. J. Sep. Sci. 2009, 32, 1175-1188.
132. Mazur, M. T., Cardasis, H. L., Spellman, D. S., Liaw, A. et al., Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry. Proc. Natl. Acad. Sci. USA 2010, 107, 7728-7733.
133. Edwards, R. L., Griffiths, P., Bunch, J., Cooper, H. J., Top-down proteomics and direct surface sampling of neonatal dried blood spots: diagnosis of unknown hemoglobin variants. J. Am. Soc. Mass Spectrom. 2012, 23, 1921-1930.
134. Zhang, J., Guy, M. J., Norman, H. S., Chen, Y. C. et al., Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure. J. Proteome Res. 2011, 10, 4054-4065.
135. Ansong, C., Wu, S., Meng, D., Liu, X. et al., Top-down proteomics reveals a unique protein S-thiolation switch in Salmonella typhimurium in response to infection-like conditions. Proc. Natl. Acad. Sci. USA 2013, 110, 10153-10158.
136. Auclair, J. R., Boggio, K. J., Petsko, G. A., Ringe, D., Agar, J. N., Strategies for stabilizing superoxide dismutase (SOD1), the protein destabilized in the most common form of familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 2010, 107, 21394-21399.
137. Borges, C. R., Oran, P. E., Buddi, S., Jarvis, J. W. et al., Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity. Clin. Chem. 2011, 57, 719-728.
138. Desiderio, C., D'Angelo, L., Rossetti, D. V., Iavarone, F. et al., Cerebrospinal fluid top-down proteomics evidenced the potential biomarker role of LVV- and VV-hemorphin-7 in posterior cranial fossa pediatric brain tumors. Proteomics 2012, 12, 2158-2166.
139. Genitori, L., Lena, G., [Cranial injuries in infants]. Soins Gynecol. Obstet. Pueric Pediatr. 1990, 107, 8-11.
140. Savaryn, J. P., Catherman, A. D., Thomas, P. M., Abecassis, M. M., Kelleher, N. L., The emergence of top-down proteomics in clinical research. Genome Med. 2013, 5, 53.
141. Messana, I., Cabras, T., Iavarone, F., Vincenzoni, F. et al., Unraveling the different proteomic platforms. J. Sep. Sci. 2013, 36, 128-139.
142. Schlautman, J. D., Rozek, W., Stetler, R., Mosley, R. L. et al., Multidimensional protein fractionation using ProteomeLab PF 2D for profiling amyotrophic lateral sclerosis immunity: a preliminary report. Proteome Sci. 2008, 6, 26.
143. Menoret, A., McAleer, J. P., Ngoi, S. M., Ray, S. et al., The oxazolidinone derivative locostatin induces cytokine appeasement. J. Immunol. 2009, 183, 7489-7496.
144. Ruelle, V., Falisse-Poirrier, N., Elmoualij, B., Zorzi, D. et al., An immuno-PF2D-MS/MS proteomic approach for bacterial antigenic characterization: to Bacillus and beyond. J. Proteome Res. 2007, 6, 2168-2175.
145. Lee, H. J., Kwon, M. S., Lee, E. Y., Cho, S. Y., Paik, Y. K., Establishment of a PF2D-MS/MS platform for rapid profiling and semiquantitative analysis of membrane protein biomarkers. Proteomics 2008, 8, 2168-2177.
146. McDonald, T., Sheng, S., Stanley, B., Chen, D. et al., Expanding the subproteome of the inner mitochondria using protein separation technologies: one- and two-dimensional liquid chromatography and two-dimensional gel electrophoresis. Mol. Cell Proteomics 2006, 5, 2392-2411.
147. Hurst, R. E., Kyker, K. D., Dozmorov, M. G., Takemori, N. et al., Proteome-level display by 2-dimensional chromatography of extracellular matrix-dependent modulation of the phenotype of bladder cancer cells. Proteome Sci. 2006, 4, 13.
148. Ornstein, D. K., Tyson, D. R., Proteomics for the identification of new prostate cancer biomarkers. Urol. Oncol. 2006, 24, 231-236.
149. Sheng, S., Chen, D., Van Eyk, J. E., Multidimensional liquid chromatography separation of intact proteins by chromatographic focusing and reversed phase of the human serum proteome: optimization and protein database. Mol. Cell Proteomics 2006, 5, 26-34.
150. Kim, M., Lee, S. H., Min, J., Kobayashi, F. et al., The utilization of Triton X-100 for enhanced two-dimensional liquid-phase proteomics. J. Biomed. Biotechnol. 2011, 2011, 213643.
151. Sanchez-Juanes, F., Muniz, M. C., Raposo, C., Rodriguez-Prieto, S. et al., Unveiling the rat urinary proteome with three complementary proteomics approaches. Electrophoresis 2013, 34, 2473-2483.
152. Menoret, A., Drew, D. A., Miyamoto, S., Nakanishi, M. et al., Differential proteomics identifies PDIA3 as a novel chemoprevention target in human colon cancer cells. Mol. Carcinog. 2012, 53 (Suppl 1), E11-E22.
153. Soldi, M., Sarto, C., Valsecchi, C., Magni, F. et al., Proteome profile of human urine with two-dimensional liquid phase fractionation. Proteomics 2005, 5, 2641-2647.
154. Lee, H. J., Kang, M. J., Lee, E. Y., Cho, S. Y. et al., Application of a peptide-based PF2D platform for quantitative proteomics in disease biomarker discovery. Proteomics 2008, 8, 3371-3381.
155. Yano, H., Kuroda, S., Buchanan, B. B., Disulfide proteome in the analysis of protein function and structure. Proteomics 2002, 2, 1090-1096.
156. Suberbielle, E., Gonzalez-Dunia, D., Pont, F., High reproducibility of two-dimensional liquid chromatography using pH-driven fractionation with a pressure-resistant electrode. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 871, 125-129.
157. Wang, L., Yang, W., Ju, W., Wang, P. et al., A proteomic study of Hutchinson-Gilford progeria syndrome: application of 2D-chromotography in a premature aging disease. Biochem. Biophys. Res. Commun. 2012, 417, 1119-1126.
158. Wang, Y., Wu, R., Cho, K. R., Shedden, K. A. et al., Classification of cancer cell lines using an automated two-dimensional liquid mapping method with hierarchical clustering techniques. Mol. Cell Proteomics 2006, 5, 43-52.
159. Deford, J. H., Nuss, J. E., Amaning, J., English, R. D. et al., High-throughput liquid-liquid fractionation of multiple protein post-translational modifications. J. Proteome Res. 2009, 8, 907-916.
160. Grebenova, D., Roselova, P., Pluskalova, M., Halada, P. et al., Proteins implicated in the increase of adhesivity induced by suberoylanilide hydroxamic acid in leukemic cells. J. Proteomics 2012, 77, 406-422.
161. Nakanishi, M., Menoret, A., Belinsky, G. S., Giardina, C. et al., Utilizing endoscopic technology to reveal real-time proteomic alterations in response to chemoprevention. Proteomics Clin. Appl. 2007, 1, 1660-1666.
162. Shin, Y. K., Lee, H. J., Lee, J. S., Paik, Y. K., Proteomic analysis of mammalian basic proteins by liquid-based two-dimensional column chromatography. Proteomics 2006, 6, 1143-1150.
163. Barre, O., Solioz, M., Improved protocol for chromatofocusing on the ProteomeLab PF2D. Proteomics 2006, 6, 5096-5098.
164. Poste, G., Biospecimens, biomarkers, and burgeoning data: the imperative for more rigorous research standards. Trends Mol. Med. 2012, 18, 717-722.
165. Fuzery, A. K., Levin, J., Chan, M. M., Chan, D. W., Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin. Proteomics 2013, 10, 13.
166. Wright, K. T., Vella, A. T., RKIP contributes to IFN-gamma synthesis by CD8+ T cells after serial TCR triggering in systemic inflammatory response syndrome. J. Immunol. 2013, 191, 708-716.
167. Beckhove, P., Warta, R., Lemke, B., Stoycheva, D. et al., Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation. J. Clin. Invest. 2010, 120, 2230-2242.
168. Falisse-Poirrier, N., Ruelle, V., ElMoualij, B., Zorzi, D. et al., Advances in immunoproteomics for serological characterization of microbial antigens. J. Microbiol. Methods 2006, 67, 593-596.
169. Kunnath-Velayudhan, S., Davidow, A. L., Wang, H. Y., Molina, D. M. et al., Proteome-scale antibody responses and outcome of Mycobacterium tuberculosis infection in nonhuman primates and in tuberculosis patients. J. Infect. Dis. 2012, 206, 697-705.
170. Pitarch, A., Nombela, C., Gil, C., Serum antibody signature directed against Candida albicans Hsp90 and enolase detects invasive candidiasis in non-neutropenic patients. J. Proteome Res. 2014, 13, 5165-5184.
171. Koerber, J. T., Thomsen, N. D., Hannigan, B. T., Degrado, W. F., Wells, J. A., Nature-inspired design of motif-specific antibody scaffolds. Nat. Biotechnol. 2013, 31, 916-921.
172. Tran, J. C., Zamdborg, L., Ahlf, D. R., Lee, J. E. et al., Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature 2011, 480, 254-258.
173. Catherman, A. D., Durbin, K. R., Ahlf, D. R., Early, B. P. et al., Large-scale top-down proteomics of the human proteome: membrane proteins, mitochondria, and senescence. Mol. Cell Proteomics 2013, 12, 3465-3473.
174. Sherma, N. D., Borges, C. R., Trenchevska, O., Jarvis, J. W. et al., Mass spectrometric immunoassay for the qualitative and quantitative analysis of the cytokine macrophage migration inhibitory factor (MIF). Proteome Sci. 2014, 12, 52.
175. Ye, H., Mandal, R., Catherman, A., Thomas, P. M. et al., Top-down proteomics with mass spectrometry imaging: a pilot study towards discovery of biomarkers for neurodevelopmental disorders. PLoS One 2014, 9, e92831.
176. Wei, B., Rogers, B. J., Wirth, M. J., Slip flow in colloidal crystals for ultraefficient chromatography. J. Am. Chem. Soc. 2012, 134, 10780-10782.
177. Wu, Z., Wei, B., Zhang, X., Wirth, M. J., Efficient separations of intact proteins using slip-flow with nano-liquid chromatography-mass spectrometry. Anal. Chem. 2014, 86, 1592-1598.
178. Chamot-Rooke, J., Mikaty, G., Malosse, C., Soyer, M. et al., Posttranslational modification of pili upon cell contact triggers N. meningitidis dissemination. Science 2011, 331, 778-782.
179. Dong, X., Sumandea, C. A., Chen, Y. C., Garcia-Cazarin, M. L. et al., Augmented phosphorylation of cardiac troponin I in hypertensive heart failure. J. Biol. Chem. 2011, 287, 848-857.
180. Bendall, S. C., Simonds, E. F., Qiu, P., Amir el, A. D. et al., Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011, 332, 687-696.
181. Han, L., Qiu, P., Zeng, Z., Jorgensen, J. L. et al., Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A 2015, 87, 346-356.
182. Angelo, M., Bendall, S. C., Finck, R., Hale, M. B. et al., Multiplexed ion beam imaging of human breast tumors. Nat. Med. 2014, 20, 436-442.
183. Giesen, C., Wang, H. A., Schapiro, D., Zivanovic, N. et al., Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry. Nat. Methods 2014, 11, 417-422.
184. Yang, P., Liu, K., Activity-based protein profiling: recent advances in probe development and applications. Chembiochem 2015, 16, 712-714.
185. Sadler, N. C., Wright, A. T., Activity-based protein profiling of microbes. Curr. Opin. Chem. Biol. 2015, 24C, 139-144.
186. Speers, A. E., Cravatt, B. F., Profiling enzyme activities in vivo using click chemistry methods. Chem. Biol. 2004, 11, 535-546.
187. Niphakis, M. J., Cravatt, B. F., Enzyme inhibitor discovery by activity-based protein profiling. Annu. Rev. Biochem. 2014, 83, 341-377.
188. Bachovchin, D. A., Ji, T., Li, W., Simon, G. M. et al., Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening. Proc. Natl. Acad. Sci. USA 2010, 107, 20941-20946.
189. Hunerdosse, D. M., Morris, P. J., Miyamoto, D. K., Fisher, K. J. et al., Chemical genetics screening reveals KIAA1363 as a cytokine-lowering target. ACS Chem. Biol. 2014, 9, 2905-2913.
190. Maaty, W. S., Steffens, J. D., Heinemann, J., Ortmann, A. C. et al., Global analysis of viral infection in an archaeal model system. Front Microbiol. 2012, 3, 411.
191. Willems, L. I., Overkleeft, H. S., van Kasteren, S. I., Current developments in activity-based protein profiling. Bioconjug. Chem. 2014, 25, 1181-1191.
192. Krysiak, J., Breinbauer, R., Activity-based protein profiling for natural product target discovery. Top Curr. Chem. 2011, 324, 43-84.
193. Gao, G., Xuan, C., Yang, Q., Liu, X. C. et al., Identification of altered plasma proteins by proteomic study in valvular heart diseases and the potential clinical significance. PLoS One 2013, 8, e72111.
194. Rosenling, T., Stoop, M. P., Attali, A., van Aken, H. et al., Profiling and identification of cerebrospinal fluid proteins in a rat EAE model of multiple sclerosis. J. Proteome Res. 2012, 11, 2048-2060.
195. Guergova-Kuras, M., Kurucz, I., Hempel, W., Tardieu, N. et al., Discovery of lung cancer biomarkers by profiling the plasma proteome with monoclonal antibody libraries. Mol. Cell Proteomics 2011, 10, M111 010298.
196. Fung, E. T., Wilson, A. M., Zhang, F., Harris, N. et al., A biomarker panel for peripheral arterial disease. Vasc. Med. 2008, 13, 217-224.
197. Silva, E., Bourin, S., Sabounchi-Schutt, F., Laurin, Y. et al., A quantitative proteomic analysis of soluble bronchoalveolar fluid proteins from patients with sarcoidosis and chronic beryllium disease. Sarcoidosis Vasc. Diffuse Lung Dis. 2007, 24, 24-32.
198. Urbonavicius, S., Lindholt, J. S., Delbosc, S., Urbonaviciene, G. et al., Proteins associated with the size and expansion rate of the abdominal aortic aneurysm wall as identified by proteomic analysis. Interact. Cardiovasc. Thorac. Surg. 2010, 11, 433-441.
199. Lessner, G., Schmitt, O., Haas, S. J., Mikkat, S. et al., Differential proteome of the striatum from hemiparkinsonian rats displays vivid structural remodeling processes. J. Proteome Res. 2010, 9, 4671-4687.
200. Kelsen, S. G., Duan, X., Ji, R., Perez, O. et al., Cigarette smoke induces an unfolded protein response in the human lung: a proteomic approach. Am. J. Respir. Cell Mol. Biol. 2008, 38, 541-550.
201. Rozek, W., Horning, J., Anderson, J., Ciborowski, P., Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairment. Proteomics Clin. Appl. 2008, 2, 1498-1507.
202. Chang, C. C., Chen, S. H., Ho, S. H., Yang, C. Y. et al., Proteomic analysis of proteins from bronchoalveolar lavage fluid reveals the action mechanism of ultrafine carbon black-induced lung injury in mice. Proteomics 2007, 7, 4388-4397.
203. Howes, J. M., Richardson, V. R., Smith, K. A., Schroeder, V. et al., Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab. Vasc. Dis. Res. 2012, 9, 216-225.
204. Cai, X. W., Shedden, K., Ao, X., Davis, M. et al., Plasma proteomic analysis may identify new markers for radiation-induced lung toxicity in patients with non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, 77, 867-876.
205. De Souza, A. I., Cardin, S., Wait, R., Chung, Y. L. et al., Proteomic and metabolomic analysis of atrial profibrillatory remodelling in congestive heart failure. J. Mol. Cell Cardiol. 2010, 49, 851-863.
206. He, P., Naka, T., Serada, S., Fujimoto, M. et al., Proteomics-based identification of alpha-enolase as a tumor antigen in non-small lung cancer. Cancer Sci. 2007, 98, 1234-1240.
207. Haas, B., Serchi, T., Wagner, D. R., Gilson, G. et al., Proteomic analysis of plasma samples from patients with acute myocardial infarction identifies haptoglobin as a potential prognostic biomarker. J. Proteomics 2011, 75, 229-236.
208. Chen, R., Vendrell, I., Chen, C. P., Cash, D. et al., Proteomic analysis of rat plasma following transient focal cerebral ischemia. Biomark. Med. 2011, 5, 837-846.
209. Kim, N., Lee, Y., Kim, H., Joo, H. et al., Potential biomarkers for ischemic heart damage identified in mitochondrial proteins by comparative proteomics. Proteomics 2006, 6, 1237-1249.
210. Noben, J. P., Dumont, D., Kwasnikowska, N., Verhaert, P. et al., Lumbar cerebrospinal fluid proteome in multiple sclerosis: characterization by ultrafiltration, liquid chromatography, and mass spectrometry. J. Proteome Res. 2006, 5, 1647-1657.
211. Cheng, J. M., Akkerhuis, K. M., Meilhac, O., Oemrawsingh, R. M. et al., Circulating osteoglycin and NGAL/MMP9 complex concentrations predict 1-year major adverse cardiovascular events after coronary angiography. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 1078-1084.
212. Cuadrado, E., Rosell, A., Penalba, A., Slevin, M. et al., Vascular MMP-9/TIMP-2 and neuronal MMP-10 up-regulation in human brain after stroke: a combined laser microdissection and protein array study. J. Proteome Res. 2009, 8, 3191-3197.
213. Xu, D., Li, Y., Li, X., Wei, L. L. et al., Serum protein S100A9, SOD3, and MMP9 as new diagnostic biomarkers for pulmonary tuberculosis by iTRAQ-coupled two-dimensional LC-MS/MS. Proteomics 2014, 15, 58-67.
214. Yin, X., Subramanian, S., Hwang, S. J., O'Donnell, C. J. et al., Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 939-945.
215. Ahn, J. M., Sung, H. J., Yoon, Y. H., Kim, B. G. et al., Integrated glycoproteomics demonstrates fucosylated serum paraoxonase 1 alterations in small cell lung cancer. Mol. Cell Proteomics 2014, 13, 30-48.
216. Cubedo, J., Ramaiola, I., Padro, T., Martin-Yuste, V. et al., High-molecular-weight kininogen and the intrinsic coagulation pathway in patients with de novo acute myocardial infarction. Thromb. Haemost. 2013, 110, 1121-1134.
217. Signor, L., Tigani, B., Beckmann, N., Falchetto, R., Stoeckli, M., Two-dimensional electrophoresis protein profiling and identification in rat bronchoalveolar lavage fluid following allergen and endotoxin challenge. Proteomics 2004, 4, 2101-2110.
218. Zamilpa, R., Lopez, E. F., Chiao, Y. A., Dai, Q. et al., Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics 2010, 10, 2214-2223.
219. Ning, M., Sarracino, D. A., Kho, A. T., Guo, S. et al., Proteomic temporal profile of human brain endothelium after oxidative stress. Stroke 2010, 42, 37-43.
220. Mundt, F., Johansson, H. J., Forshed, J., Arslan, S. et al., Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma. Mol. Cell Proteomics 2013, 13, 701-715.
221. Martin-Rojas, T., Gil-Dones, F., Lopez-Almodovar, L. F., Padial, L. R. et al., Proteomic profile of human aortic stenosis: insights into the degenerative process. J. Proteome Res. 2012, 11, 1537-1550.
222. Passadore, I., Iadarola, P., Di Poto, C., Giuliano, S. et al., 2-DE and LC-MS/MS for a comparative proteomic analysis of BALf from subjects with different subsets of inflammatory myopathies. J. Proteome Res. 2009, 8, 2331-2340.
223. Giusti, L., Da Valle, Y., Bonotti, A., Donadio, E. et al., Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament-related proteins. Proteomics Clin. Appl. 2014, 8, 258-268.